Expression of α-Klotho protein in human thyroid cancers — an immunohistochemical study
Abstract
Introduction: The α-Klotho protein was discovered as a gene controlling the process of aging, but further studies indicated that it also plays the role of a tumour suppressor. Although numerous studies were performed on the role of the α-Klotho gene and protein in neoplasia, the data on α-Klotho protein expression in thyroid cancers are very scarce. Our study presents the immunohistochemical investigation of α-Klotho expression in benign and malignant thyroid tumours.
Material and methods: The material included samples of benign (nodular hyperplasia, follicular adenoma), differentiated (follicular and papillary) cancers and aggressive thyroid cancers of low differentiation grade. The samples were immunostained using two different monoclonal anti-α-Klotho antibodies.
Results: From the two antibodies used in this study, one (EPR6856) reacted probably with the soluble form of Klotho and immunostained mostly the colloid filling thyroid follicles and intravascular or extravascular serum deposits. The other (A-9 antibody) immunostained the follicular epithelium in benign thyroid lesions as well as the epithelial tumoural cells in differentiated thyroid (follicular and papillary cancers). In the thyroid cancers of high malignancy, the immunostaining with A-9 anti-α-Klotho antibody was (except in one case) negative or very weak.
Conclusion: Our results indicate that lowered expression of a- Klotho is involved in the process of thyroid neoplasia.
Keywords: α-Klothothyroid malignanciesimmunohistochemistry
References
- Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655): 45–51.
- Abramovitz L, Rubinek T, Ligumsky H, et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res. 2011; 17(13): 4254–4266.
- Wolf I, Levanon-Cohen S, Bose S, et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 2008; 27(56): 7094–7105.
- Bartke A, Kopchick J, Dominici F, et al. IGF-1 and Insulin Signaling in the Control of Longevity. In: Endocrine aspects of successful aging: genes, hormones and lifestyles. P. Chanson, J. Epelbaum, S. Lamberts, Y. Christen (ed). Springer Berlin 2004: 19–33.
- Zhou X, Wang X. Klotho: a novel biomarker for cancer. J Cancer Res Clin Oncol. 2015; 141(6): 961–969.
- Rubinek T, Wolf I. The role of alpha-klotho as a universal tumor suppressor. Vitam Horm. 2016; 101: 197–214.
- Dai D, Wang Qi, Li X, et al. Klotho inhibits human follicular thyroid cancer cell growth and promotes apoptosis through regulation of the expression of stanniocalcin-1. Oncol Rep. 2016; 35(1): 552–558.
- Adhikari BR, Uehara O, Matsuoka H, et al. Immunohistochemical evaluation of Klotho and DNA methyltransferase 3a in oral squamous cell carcinomas. Med Mol Morphol. 2017; 50(3): 155–160.
- Lim K, Groen A, Molostvov G, et al. α-klotho expression in human tissues. J Clin Endocrinol Metab. 2015; 100(10): E1308–E1318.
- Abcam. Product datasheet. Anti-Klotho antibody [EPR 6856] ab181373.
- Matsumura Y, Aizawa H, Shiraki-Iida T, et al. Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem Biophys Res Commun. 1998; 242(3): 626–630.
- Szymczyk A, Forma E. Structure and function of Klotho protein [in Polish]. Folia Medica Lodzensia. 2012; 19: 151–187.
- Jiang B, Gu Y, Chen Y. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma. Cancer Invest. 2014; 32(6): 218–225.
- Lee J, Jeong DJ, Kim J, et al. The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer. 2010; 9: 109.
- Wang L, Wang X, Wang X, et al. Klotho is silenced through promoter hypermethylation in gastric cancer. Am J Cancer Res. 2011; 1(1): 111–119.
- Motylewska E, Stępień T, Borkowska M, et al. Alteration in the serum concentrations of FGF19, FGFR4 and βKlotho in patients with thyroid cancer. Cytokine. 2018; 105: 32–36.
